# RAB001（LLP2A-Ale） in Healthy Subjects

> **NCT07545018** · PHASE1 · COMPLETED · sponsor: **ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd.** · enrollment: 16 (actual)

## Conditions studied

- Osteonecrosis of the Femoral Head

## Interventions

- **DRUG:** RAB001 400 μg/kg group
- **DRUG:** RAB001 750 μg/kg group
- **DRUG:** Normal saline

## Key facts

- **NCT ID:** NCT07545018
- **Lead sponsor:** ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd.
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-10
- **Primary completion:** 2023-07-05
- **Final completion:** 2023-07-05
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07545018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07545018, "RAB001（LLP2A-Ale） in Healthy Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07545018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*